Abstract
Alternative and effective MDA regimens and strategies will be needed if the GPELF is to achieve the goals of global elimination of lymphatic filariasis by 2020. Further research to test new drug regimens (including single high doses of albendazole) or alternative treatment regimens (including biannual treatment schedules) may also be necessary. A new drug, moxidectin, which is currently under development for use against onchocerciasis, may be effective against lymphatic filariasis.
| Original language | English |
|---|---|
| Pages (from-to) | 617-620 |
| Number of pages | 4 |
| Journal | Current Opinion in Infectious Diseases |
| Volume | 23 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1 Dec 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- albendazole
- diethylcarbamazine
- doxycycline and elimination
- Global Programme to Eliminate Lymphatic Filariasis
- ivermectin
- lymphatic filariasis
- onchocerciasis
Fingerprint
Dive into the research topics of 'Elimination of lymphatic filariasis: do we have the drugs to complete the job?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver